Teva Pharmaceutical Industries
TEVA
537 hedge funds and large institutions have $16.3B invested in Teva Pharmaceutical Industries in 2018 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 175 increasing their positions, 158 reducing their positions, and 48 closing their positions.
73% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 48
60% more funds holding in top 10
Funds holding in top 10: 10 → 16 (+6)
11% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 158
6% more funds holding
Funds holding: 505 → 537 (+32)
0.35% less ownership
Funds ownership: 60.98% → 60.64% (-0.35%)
6% less capital inflows, than outflows
Capital inflows: $1.12B | Capital outflows: $1.19B
20% less call options, than puts
Call options by funds: $614M | Put options by funds: $765M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PointState Capital
New York
|
+$136M |
| 2 |
Millennium Management
New York
|
+$113M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$83.9M |
| 4 |
Citigroup
New York
|
+$81.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$76.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$330M |
| 2 |
Highfields Capital Management
Boston,
Massachusetts
|
-$206M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$173M |
| 4 |
NC
Northern Cross
Boston,
Massachusetts
|
-$40.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.8M |
TEVA Hedge Fund Activity: Q2 2018 in Review
537 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries (TEVA) for Q2 2018, worth a combined $16.3B — up 41% from $11.5B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new TEVA positions and 48 closed out — a net gain of 35 holders — while 175 added to existing stakes and 158 trimmed.
The largest buyer was PointState Capital, opening a new position worth an estimated $136M. The largest seller was JP Morgan Chase, cutting an estimated $330M.
- 537 institutional investors held Teva Pharmaceutical Industries (TEVA) as of Q2 2018, up from 505 in Q1 2018.
- Funds reported $16.3B of Teva Pharmaceutical Industries stock for Q2 2018, up 41% quarter-over-quarter.
- 83 funds opened new Teva Pharmaceutical Industries positions in Q2 2018 and 48 closed out, a net change of +35 holders.
- The largest Teva Pharmaceutical Industries buyer in Q2 2018 was PointState Capital, an estimated $136M added.
- The largest Teva Pharmaceutical Industries seller in Q2 2018 was JP Morgan Chase, an estimated $330M sold.
Based on aggregated 13F filings for Q2 2018.